Liquidia Stock (NASDAQ:LQDA)
Previous Close
$14.20
52W Range
$8.26 - $16.99
50D Avg
$11.61
200D Avg
$11.66
Market Cap
$1.21B
Avg Vol (3M)
$846.76K
Beta
0.20
Div Yield
-
LQDA Company Profile
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
LQDA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| KALV | KalVista Pharmaceuticals, Inc. |
| GOSS | Gossamer Bio, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |
| NRXP | NRx Pharmaceuticals, Inc. |
| KRON | Kronos Bio, Inc. |
| MIRM | Mirum Pharmaceuticals, Inc. |
| IMCR | Immunocore Holdings plc |
| TECH | Bio-Techne Corporation |
| AGEN | Agenus Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| REPL | Replimune Group, Inc. |
| LEGN | Legend Biotech Corporation |
| BMRN | BioMarin Pharmaceutical Inc. |
| INZY | Inozyme Pharma, Inc. |
| NVCT | Nuvectis Pharma, Inc. |
| PCVX | Vaxcyte, Inc. |
| UTHR | United Therapeutics Corporation |
| ABOS | Acumen Pharmaceuticals, Inc. |
| GERN | Geron Corporation |